Open AccessCCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells
Author(s) -
Muhammad Usama Tariq,
Muhammad Furqan,
Hira Parveen,
Rahim Ullah,
Muhammad Muddassar,
Rahman Shah Zaib Saleem,
Vassilios Bavetsias,
Spiros Linardopoulos,
Amir Faisal
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01527-2
Subject(s) - cancer research , aurora kinase , survivin , cell culture , syk , fms like tyrosine kinase 3 , aurora inhibitor , kinase , biology , tyrosine kinase , cell , cell cycle , mutation , signal transduction , microbiology and biotechnology , biochemistry , genetics , gene
Activating mutations in the Fms-like tyrosine kinase 3 (FLT3) are among the most prevalent oncogenic mutations in acute myeloid leukaemia. Inhibitors selectively targeting FLT3 kinase have shown promising clinical activity; their success in the clinic, however, has been limited due to the emergence of acquired resistance.